Riskpilot← Back to searchSign inGet full accessXcelCyte A/S
A/SIn liquidationCVR 41466162Søndergade 74, 5.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201 employeeswww.xcelcyte.com
Revenue 2024
DKK -17K
-20% vs 2023
EBITDA margin
100.0%
+20% vs 2023
Equity ratio
-10.0%
Financial strength
Net profit 2024
DKK -19K
+47% vs 2023
| Revenue | DKK -17K | -20% |
| EBITDA | DKK -17K | +20% |
| Net profit | DKK -19K | +47% |
| Total assets | DKK 189K | -12% |
| Equity | DKK -19K | -5730% |
| Employees | 1 | — |
Legal name
XcelCyte A/S
CVR number
41466162
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26. juni 2020
Share capital
DKK 460.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at forske i, udvikle, producere og markedsføre medicinske, farmaceutiske, gen- og celleterapi, samt tekniske produkter og service ydelser samt anden dertil knyttet virksomhed efter bestyrelsens nærmere bestemmelse.
Address
Søndergade 74, 5.
Website
www.xcelcyte.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -2.628 | -2.215 | -78 | -21 | -17 |
| Staff expenses | -237 | -236 | -0 | -0 | -0 |
| EBITDA | -2.865 | -2.451 | -78 | -21 | -17 |
| Depreciation & amort. | -64 | -48 | -0 | -0 | -0 |
| EBIT | -2.930 | -2.499 | -78 | -21 | -17 |
| Net financials | -10 | -103 | -80 | -16 | -3 |
| Profit before tax | -2.940 | -2.603 | -157 | -36 | -19 |
| Tax | -592 | -544 | -0 | -0 | -0 |
| Net profit | -2.348 | -2.058 | -157 | -36 | -19 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.594 | 927 | 282 | 213 | 189 |
| Equity | 2.252 | 194 | 37 | 0 | -19 |
| Long-term debt | 9 | 0 | 0 | 0 | 0 |
| Short-term debt | 333 | 733 | 245 | 213 | 207 |
| Total debt | 342 | 733 | 245 | 213 | 207 |
EBITDA margin
-1652600.0%
This company
15.8%
Market median
-10459594% vs market
20202024
Equity ratio
-10.0%
This company
38.2%
Market median
-126% vs market
20202024
Return on equity
-1925400.0%
This company
18.4%
Market median
-10464230% vs market
20202024
Net profit margin
-1925400.0%
This company
8.1%
Market median
-23770470% vs market
20202024
Asset turnover
-0.09×
This company
1.12×
Market median
-108% vs market
20202024
Debt / equity
10.96×
This company
0.62×
Market median
-1668% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-06-26 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HH Unofficial title | Unofficial title | 2023 | — | — |
NC Founder | Founder | 2020 | — | — |
CG Founder | Founder | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2020 | |
LILLE FREDERIKSLUND INVEST ApS | Company | 33.3% | 33.3% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LILLE FREDERIKSLUND INVEST ApS
XcelCyte A/S Board members of XcelCyte A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Henrik Højrup Bondegaard | Unofficial title | 0 companies |
| Neil Charles Boughton | Founder | 0 companies |
| Christian Gunni Pedersen | Founder | 0 companies |
| Per Falholt | Board of Directors | 0 companies |
| David Carl Christian von Kauffmann | Chairman | 0 companies |
| Jesper Brinkmann | Board of Directors | 0 companies |